Ferrus calcium citrate is absorbed better than iron bisglycinate in patients with Crohn's disease, but not in healthy controls

Digestive Diseases and Sciences

Volumn 51, Issue 5, 2006, Pages 942-945

  Chermesh, Irit ^a,b   Tamir, Ada ^a   Suissa, Alain ^a   Eliakim, Rami ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Crohn's disease; Ferrous calcium citrate; Ferrum bisglycinate; Iron deficiency anemia; Iron salt; Iron tolerance test

Indexed keywords

FERROUS CALCIUM CITRATE; IRON; IRON BISGLYCINATE; IRON DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; FEMALE; FUNCTION TEST; GASTROINTESTINAL SYMPTOM; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; MALE; NAUSEA; ORAL IRON TOLERANCE TEST; PRIORITY JOURNAL;

ADULT; AREA UNDER CURVE; CALCIUM CITRATE; CROHN DISEASE; FEMALE; FERROUS COMPOUNDS; GLYCINE; HUMANS; INTESTINAL ABSORPTION; IRON; MALE; TRANSFERRIN;

EID: 33745870846     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-9036-6     Document Type: Article

References (27)

1. Beutler E, Hoffbrand AV, Cook JD (2003) Iron deficiency and overload. Hematology (Am Soc Hematol Educ Progr) 40-61
2. Zoller H, Theurl I, Koch R, Kaser A, Weiss G (2002) Mechanisms of iron mediated regulation of the duodenal iron transporters divalent metal transporter 1 and ferroportin 1. Blood Cells Mol Dis 29:488-497
3. Leong WI, Lonnerdal B (2004) Hepcidin, the recently identified peptide that appeal's to regulate iron absorption. Br J Nutr 134:1-4
4. Lomer MC, Kodjabashia K, Hutchinson C, Greenfield SM, Thompson RP, Powell JJ (2004) Intake of dietary iron is low in patients with Crohn's disease: A case-control study. Br J Nutr 91:141-148
5. Gasche C, Lomer MC, Cavill I, Weiss G (2004) Iron, anaemia, and inflammatory bowel diseases. Gut 53:1190-1197
6. Maslovsky I (2005) Intravenous iron in a primary-care clinic. Am J Hematol 78:261-264
7. Wilson A, Reyes E, Ofman J (2004) Prevalence and outcomes of anemia in inflammatory bowel disease: A systematic review of the literature. Am J Med 116(Suppl 7A):44S-49S
8. de Silva AD, Mylonaki M, Rampton DS (2003) Oral iron therapy in inflammatory bowel disease: Usage, tolerance, and efficacy. Inflamm Bowel Dis 9:316-320
9. Bodemar G, Kechagias S, Almer S, Danielson BG (2004) Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 39:454-458
10. Eschbach JW (2005) Iron requirements in erythropoietin therapy. Best Pract Res Clin Haematol 18:347-361
11. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O (2004) The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int [Epub ahead of print, Aug 12]
12. Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD (2002) Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: Improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 15(100):474-482
13. Domenech E, Manosa M, Masnou H, Navarro M, Garcia-Planella E, Bernal I, Gassull MA (2005) Infliximab for the treatment of chronic anemia in Crohn's disease. Am J Gastroenterol 100:496
14. Jeppsen RB (2001) Toxicology and safety of Ferrochel and other iron amino acid chelates. Arch Latinoam Nutr 51(Suppl 1):26-34
15. Ashmead HD (2001) The absorption and metabolism of iron amino acid chelate. Arch Latinoam Nutr 51 (Suppl 1):13-21
16. Pizarro F, Olivares M, Hertrampf E, Mazariegos DI, Arredondo M, Letelier A, Gidi V (2002) Iron bis-glycine chelate competes for the nonheme-iron absorption pathway. Am J Clin Nutr 76:577-581
17. Pineda O (2003) Iron bis-glycine chelate competes for the nonheme-iron absorption pathway. Am J Clin Nutr 78:495-496
18. Miglioranza LH, Matsuo T, Caballero-Cordoba GM, Dichi JB, Cyrino ES, Oliveira IB, Martins MS, Polezer NM, Dichi I (2003) Effect of long-term fortification of whey drink with ferrous bisglycinate on anemia prevalence in children and adolescents from deprived areas in Londrina, Parana, Brazil. Nutrition 19:419-421
19. Pineda O, Ashmead HD (2001) Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bisglycinate chelate. Nutrition 17:381-384
20. Bovell-Benjamin AC, Viteri FE, Allen LH (2000) Iron absorption from ferrous bisglycinate and ferric trisglycinate in whole maize is regulated by iron status. Am J Clin Nutr 71:1563-1569
21. Hallberg L, Hulthén L (2000) No advantage of using ferrous bisglycinate as an iron fortificant. Am J Clin Nutr 72:1592-1593
22. McDiarmid T, Johnson ED (2002) Are any oral iron formulations better tolerated than ferrous sulfate? J Fam Pract 51:576
23. Hallberg L, Ryttinger L, Solvell L (1966) Side-effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. Acta Med Scand Suppl 459:3-10
24. Harvey RS, Reffitt DM, Doig LA, Meenan J, Ellis RD, Thompson RP, Powell JJ (1998) Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther 12:845-848
25. Shatrugna V, Raman L, Kailash U, Balakrishna N, Rao KV (1999) Effect of dose and formulation on iron tolerance in pregnancy. Natl Med J India 12:18-20
26. Hyder SM, Persson LA, Chowdhury AM, Ekstrom EC (2002) Do side-effects reduce compliance to iron supplementation? A study of daily- and weekly-dose regimens in pregnancy. J Health Popul Nutr 20:175-179
27. Cook JD, Lipschitz DA, Skikne BS (1982) Absorption of controlled-release iron. Clin Pharmacol Ther 32:531-539